preferable to recover and store additional doses for later use in these patients.
A new gold-induced ACS product (serum combined with gold particles) has
been developed by Arthrogen (GOLDIC). It has been claimed that the gold
particles have an immunomodulatory effect and trigger the production of
gelsolin, an actin-binding protein that is a key regulator of actin filament
assembly and disassembly. Preliminary research at the University of Zurich
has yielded promising results for alleviation of joint pain.
Dr. Thomas Weinberger, a German equine practitioner has formulated to
following dosage chart for the use of ACS/IRAP:
Coffin joint
Pastern joint
Fetlock joint
Carpal joint
Elbow joint
Shoulder joint
TMT joint
Tarsocrural
Stifle
Hip joint
amount/injection:
Repeats; intervals
a: 4 – 6 ml
a: 2 – 4 ml
a: 4 – 6 ml
a: 2 – 4 ml
a: 4 – 6 ml
a: 4 – 8 ml
a: 1 – 2 ml
a: 6 – 8 ml
a: 4 – 8 ml
a: 4 – 8 ml
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 8 – 14 days
r: 2 – 3x; 12 – 21
days
Platelet-Rich Plasma (PRP)
Platelet rich plasma (PRP) is increasing in popularity as a therapy in equine
lameness practice. A number of systems and techniques are available in the
horse for production of PRP, using either centrifugation or filtration. A recent
paper has demonstrated a wide variation in the number of platelets,
leukocytes and growth factor levels between the different systems
commercially available in equine practice, with one of the most popular
systems hardly containing any increase in platelet or growth factor
concentrations over whole blood (Hessel et al. 2014). Whilst such therapies
are more frequently used in treatment of tendon and ligament injuries, PRP is
also being increasingly used for treatment of mild to moderate osteoarthritis. It
may be beneficial in cases with early cartilage pathology as opposed to
established OA. However, as one of the main growth factors released by
platelets is transforming growth factor-b, a growth factor with known profibrotic effects, intra-articular use needs further evaluation before it can be
recommended in clinical practice.
Bone Marrow-Derived Mesenchymal Stromal Cells
The use of intra-articularly administered mesenchymal stem cells (MSCs) is
currently gaining some attention. There is some compelling evidence for
efficacy of such therapy from a goat model of meniscal injury (Murphy et al.
2003). The mechanism of potential benefit of MSCs is unclear, but they are
15-‐18
February
2016
East
London
Convention
Centre,
East
London,
South
Africa
160